Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Nanotoxicology data for in silico tools: a literature review.

Furxhi I, Murphy F, Mullins M, Arvanitis A, Poland CA.

Nanotoxicology. 2020 Feb 26:1-26. doi: 10.1080/17435390.2020.1729439. [Epub ahead of print]

PMID:
32100604
2.

Practices and Trends of Machine Learning Application in Nanotoxicology.

Furxhi I, Murphy F, Mullins M, Arvanitis A, Poland CA.

Nanomaterials (Basel). 2020 Jan 8;10(1). pii: E116. doi: 10.3390/nano10010116. Review.

3.

Ultrathin ZSM-5 zeolite nanosheet laminated membrane for high-flux desalination of concentrated brines.

Cao Z, Zeng S, Xu Z, Arvanitis A, Yang S, Gu X, Dong J.

Sci Adv. 2018 Nov 23;4(11):eaau8634. doi: 10.1126/sciadv.aau8634. eCollection 2018 Nov.

4.

Equity Theory Ratios as Causal Schemas.

Arvanitis A, Hantzi A.

Front Psychol. 2016 Aug 19;7:1257. doi: 10.3389/fpsyg.2016.01257. eCollection 2016.

5.

Exophytic growths on the back.

Rallis E, Arvanitis A.

Am Fam Physician. 2015 Apr 1;91(7):487-8. No abstract available.

6.

Application of the maximum cumulative ratio (MCR) as a screening tool for the evaluation of mixtures in residential indoor air.

De Brouwere K, Cornelis C, Arvanitis A, Brown T, Crump D, Harrison P, Jantunen M, Price P, Torfs R.

Sci Total Environ. 2014 May 1;479-480:267-76. doi: 10.1016/j.scitotenv.2014.01.083. Epub 2014 Feb 22.

PMID:
24565859
7.

miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.

Salim H, Arvanitis A, de Petris L, Kanter L, Hååg P, Zovko A, Özata DM, Lui WO, Lundholm L, Zhivotovsky B, Lewensohn R, Viktorsson K.

Genes Chromosomes Cancer. 2013 Oct;52(10):895-911. doi: 10.1002/gcc.22085. Epub 2013 Aug 9.

PMID:
23929716
8.

Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists.

Dzierba CD, Sielecki TM, Arvanitis AG, Galka A, Johnson TL, Takvorian AG, Rafalski M, Kasireddy-Polam P, Vig S, Dasgupta B, Zhang G, Molski TF, Wong H, Zaczek RC, Lodge NJ, Combs AP, Gilligan PJ, Trainor GL, Bronson JJ, Macor JE.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):4986-9. doi: 10.1016/j.bmcl.2012.06.034. Epub 2012 Jun 16.

PMID:
22749422
9.

The role of paricalcitol on proteinuria.

Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P.

J Ren Care. 2011 Jun;37(2):80-4. doi: 10.1111/j.1755-6686.2011.00229.x.

PMID:
21561543
10.

Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection.

Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P.

J Ren Care. 2011 Mar;37(1):25-9. doi: 10.1111/j.1755-6686.2011.00209.x.

PMID:
21288314
11.

Reversal of refractory sulfasalazine-related renal failure after treatment with corticosteroids.

Alivanis P, Aperis G, Lambrianou F, Zervos A, Paliouras C, Karvouniaris N, Arvanitis A.

Clin Ther. 2010 Oct;32(11):1906-10. doi: 10.1016/j.clinthera.2010.10.002.

PMID:
21095485
12.

The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients.

Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P.

J Ren Care. 2010 Dec;36(4):180-5. doi: 10.1111/j.1755-6686.2010.00190.x.

PMID:
20969735
13.

Interdigital basal cell carcinoma of the hand: a rare site.

Rallis E, Nasiopoulou A, Arvanitis A.

Indian J Dermatol Venereol Leprol. 2010 Sep-Oct;76(5):593. doi: 10.4103/0378-6323.69099. No abstract available.

14.

Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans.

Shilling AD, Nedza FM, Emm T, Diamond S, McKeever E, Punwani N, Williams W, Arvanitis A, Galya LG, Li M, Shepard S, Rodgers J, Yue TY, Yeleswaram S.

Drug Metab Dispos. 2010 Nov;38(11):2023-31. doi: 10.1124/dmd.110.033787. Epub 2010 Aug 10.

PMID:
20699411
16.

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, Sparks RB, Arvanitis A, Rogers JD, Combs AP, Vaddi K, Solomon KA, Scherle PA, Newton R, Fridman JS.

Neoplasia. 2010 Jan;12(1):28-38.

17.

Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.

Hartz RA, Ahuja VT, Arvanitis AG, Rafalski M, Yue EW, Denhart DJ, Schmitz WD, Ditta JL, Deskus JA, Brenner AB, Hobbs FW, Payne J, Lelas S, Li YW, Molski TF, Mattson GK, Peng Y, Wong H, Grace JE, Lentz KA, Qian-Cutrone J, Zhuo X, Shu YZ, Lodge NJ, Zaczek R, Combs AP, Olson RE, Bronson JJ, Mattson RJ, Macor JE.

J Med Chem. 2009 Jul 23;52(14):4173-91. doi: 10.1021/jm900301y.

PMID:
19552437
18.

In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.

Hartz RA, Ahuja VT, Rafalski M, Schmitz WD, Brenner AB, Denhart DJ, Ditta JL, Deskus JA, Yue EW, Arvanitis AG, Lelas S, Li YW, Molski TF, Wong H, Grace JE, Lentz KA, Li J, Lodge NJ, Zaczek R, Combs AP, Olson RE, Mattson RJ, Bronson JJ, Macor JE.

J Med Chem. 2009 Jul 23;52(14):4161-72. doi: 10.1021/jm900302q. Erratum in: J Med Chem. 2009 Sep 24;52(18):5770.

PMID:
19552436
19.

Relation between insomnia mood disorders and clinical and biochemical parameters in patients undergoing chronic hemodialysis.

Bornivelli C, Alivanis P, Giannikouris I, Arvanitis A, Choustoulakis I, Georgopoulou K, Karvouniaris N, Zervos A.

J Nephrol. 2008 Mar-Apr;21 Suppl 13:S78-83.

PMID:
18446737
20.

Issues in consumer exposure modeling: towards harmonization on a global scale.

Kephalopoulos S, Bruinen de Bruin Y, Arvanitis A, Hakkinen P, Jantunen M.

J Expo Sci Environ Epidemiol. 2007 Dec;17 Suppl 1:S90-100. Epub 2007 Aug 1.

PMID:
17668010
21.
22.

Metformin-associated lactic acidosis treated with continuous renal replacement therapy.

Alivanis P, Giannikouris I, Paliuras C, Arvanitis A, Volanaki M, Zervos A.

Clin Ther. 2006 Mar;28(3):396-400.

PMID:
16750454
23.

Quail poisoning in a child.

Giannopoulos D, Voulioti S, Skarpelos A, Arvanitis A, Chalkiopoulou C.

Rural Remote Health. 2006 Apr-Jun;6(2):564. Epub 2006 May 15.

24.

Oral administration of cyclosporin A in patients with severe alopecia areata.

Rallis E, Nasiopoulou A, Kouskoukis C, Roussaki-Schulze A, Koumantaki E, Karpouzis A, Arvanitis A.

Int J Tissue React. 2005;27(3):107-10.

PMID:
16372476
25.

Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands.

Hartz RA, Arvanitis AG, Arnold C, Rescinito JP, Hung KL, Zhang G, Wong H, Langley DR, Gilligan PJ, Trainor GL.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):934-7. Epub 2005 Nov 16.

PMID:
16297619
26.

Bilateral congenital megacalycosis in a young male patient.

Alivanis P, Giannikouris I, Arvanitis A, Volanaki M, Zervos A, Paliuras C.

Nephrol Dial Transplant. 2006 May;21(5):1446-7. Epub 2005 Nov 17. No abstract available.

PMID:
16293636
27.

Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%.

Rallis E, Nasiopoulou A, Kouskoukis C, Roussaki-Schulze A, Koumantaki E, Karpouzis A, Arvanitis A.

Drugs Exp Clin Res. 2005;31(4):141-5.

PMID:
16223203
28.

Pustular impetigo with good response to clarithromycin.

Rallis E, Nasiopoulou A, Tsiambas E, Arvanitis A.

Drugs Exp Clin Res. 2004;30(2):43-5.

PMID:
15272641
29.

Intravenous administration of vitamin B12 in the treatment of hyperhomocysteinemia associated with end-stage renal disease.

Vrentzos GE, Papadakis JA, Vardakis KE, Maliaraki N, Stilianou K, Arvanitis A, Sratigis S, Alivanis P, Margioris AN, Ganotakis ES.

J Nephrol. 2003 Jul-Aug;16(4):535-9.

PMID:
14696755
30.

Epidermal growth factor-induced epithelio-mesenchymal transition in human breast carcinoma cells.

Ackland ML, Newgreen DF, Fridman M, Waltham MC, Arvanitis A, Minichiello J, Price JT, Thompson EW.

Lab Invest. 2003 Mar;83(3):435-48.

31.

CRF ligands via Suzuki and Negishi couplings of 3-pyridyl boronic acids or halides with 2-benzyloxy-4-chloro-3-nitropyridine.

Arvanitis AG, Arnold CR, Fitzgerald LW, Frietze WE, Olson RE, Gilligan PJ, Robertson DW.

Bioorg Med Chem Lett. 2003 Jan 20;13(2):289-91.

PMID:
12482442
32.

Salzmann's nodular degeneration of the cornea.

Jaworski A, Arvanitis A.

Clin Exp Optom. 1999 Jan-Feb;82(1):14-16.

PMID:
12482303
33.

Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands.

Arvanitis AG, Rescinito JT, Arnold CR, Wilde RG, Fitzgerald LW, Zaczek R, Hartig PR, Grossman S, Arneric SP, Gilligan PJ, Olson RE, Robertson DW.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):129-31.

PMID:
12467632
34.

Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands.

Arvanitis AG, Rescinito JT, Arnold CR, Wilde RG, Cain GA, Sun JH, Yan JS, Teleha CA, Fitzgerald LW, McElroy J, Zaczek R, Hartig PR, Grossman S, Arneric SP, Gilligan PJ, Olson RE, Robertson DW.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):125-8.

PMID:
12467631
35.

An epidemiological study of syphilis incognito, an emerging public health problem in Greece.

Stratigos JD, Katoulis AC, Hasapi V, Stratigos AJ, Arvanitis A, Vounatsou M, Hadjivassiliou M, Katsambas AD, Stavrianeas NG.

Arch Dermatol. 2001 Feb;137(2):157-60.

PMID:
11176687
36.

Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists.

Beck JP, Arvanitis AG, Curry MA, Rescinito JT, Fitzgerald LW, Gilligan PJ, Zaczek R, Trainor GL.

Bioorg Med Chem Lett. 1999 Apr 5;9(7):967-72.

PMID:
10230622
37.

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.

Chorvat RJ, Bakthavatchalam R, Beck JP, Gilligan PJ, Wilde RG, Cocuzza AJ, Hobbs FW, Cheeseman RS, Curry M, Rescinito JP, Krenitsky P, Chidester D, Yarem JA, Klaczkiewicz JD, Hodge CN, Aldrich PE, Wasserman ZR, Fernandez CH, Zaczek R, Fitzgerald LW, Huang SM, Shen HL, Wong YN, Chien BM, Arvanitis A, et al.

J Med Chem. 1999 Mar 11;42(5):833-48.

PMID:
10072681
38.

Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.

Hodge CN, Aldrich PE, Wasserman ZR, Fernandez CH, Nemeth GA, Arvanitis A, Cheeseman RS, Chorvat RJ, Ciganek E, Christos TE, Gilligan PJ, Krenitsky P, Scholfield E, Strucely P.

J Med Chem. 1999 Mar 11;42(5):819-32.

PMID:
10072680
39.

Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.

Arvanitis AG, Gilligan PJ, Chorvat RJ, Cheeseman RS, Christos TE, Bakthavatchalam R, Beck JP, Cocuzza AJ, Hobbs FW, Wilde RG, Arnold C, Chidester D, Curry M, He L, Hollis A, Klaczkiewicz J, Krenitsky PJ, Rescinito JP, Scholfield E, Culp S, De Souza EB, Fitzgerald L, Grigoriadis D, Tam SW, Shen HL, et al.

J Med Chem. 1999 Mar 11;42(5):805-18.

PMID:
10072679
40.

Nephrotic syndrome caused by minimal-change disease in a patient with focal proliferative SLE nephritis (WHO III) in remission.

Perakis C, Arvanitis A, Sotsiou F, Emmanouel DS.

Nephrol Dial Transplant. 1998 Feb;13(2):467-70. No abstract available.

PMID:
9509465
41.

Change in the epidemiology of Reiter's syndrome (reactive arthritis) in the post-AIDS era? An analysis of cases appearing in the Greek Army.

Iliopoulos A, Karras D, Ioakimidis D, Arvanitis A, Tsamis N, Iakovou I, Anagnostopoulos I, Giannikos N.

J Rheumatol. 1995 Feb;22(2):252-4.

PMID:
7738947
42.

Malignant syphilis in HIV-infected patients.

Tosca A, Stavropoulos PG, Hatziolou E, Arvanitis A, Stavrianeas N, Hatzivassiliou M, Stratigos JD.

Int J Dermatol. 1990 Oct;29(8):575-8. No abstract available.

PMID:
2242946

Supplemental Content

Loading ...
Support Center